Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6195619 | 0.87 | KMT2A (0.47) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL2020438 | 0.84 | KMT2A (0.71) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL2017369 | 0.84 | KMT2A (0.71) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL2021172 | 0.83 | KMT2A (0.70) | KMT2AMEN1NPC1RAB9AHTT | |
| SCHEMBL6289957 | 0.81 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL11244456 | 0.81 | MEN1 (0.68) | KMT2AMEN1KDM4EHTTMAPT | |
| SCHEMBL6537339 | 0.81 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AHTT | |
| SCHEMBL6293263 | 0.81 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AHTT | |
| SCHEMBL2719292 | 0.81 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9ARECQL | |
| SCHEMBL528848 | 0.81 | HAVCR2 (0.49) | KMT2AMEN1RAB9AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10087166-B2 | Cyclic amine azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2018-10-02 | — | — | US | disclosed |
| US-20170129877-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2017-05-11 | — | — | US | disclosed |
| US-9586938-B2 | Cyclic amine azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20130217709-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| EP-2598497-A1 | CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES | Merck Patent GmbH (DE) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016001-A1 | CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2012-02-02 | — | — | WO | disclosed |
| US-4343804-A | 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds | A. H. ROBINS COMPANY, INC. (US) | 1982-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217709-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MKI67, AZI2, PCNA | KMT2A 105/4885MEN1 563/4885NPC1 3168/4885 |
| US-20170129877-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MKI67, AZI2, PCNA | KMT2A 105/4885MEN1 563/4885NPC1 3168/4885 |
| US-10087166-B2 | Cyclic amine azaheterocyclic carboxamides | MKI67, AZI2, PCNA | KMT2A 105/4885MEN1 563/4885NPC1 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.